Massively overvalued by what measure? By how much income we are currently generating?
Because it's sure as hell not overvalued based on the potential income of one or multiple of our products reaching production. Success rates for bio-med stocks are low, but let's not pretend that the trials have gone poorly, or that company performance has been lackluster.
Speculative stocks are extremely hard to value and are heavily swayed by market conditions. The reality is that the value of this company will flip on a dime, dependent on trial results. I'm keen to keep holding and see.